Related Experiment Video

Updated: Jun 6, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Management of pulmonary arterial hypertension in children

M T R Roofthooft1, R L E van Loon, R M F Berger

  • 1Department of Paediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, The Netherlands. M.T.R.Roofthooft@BKK.UMCG.nl

Paediatric Respiratory Reviews
|November 27, 2010
PubMed

Insights

New anti-Pulmonary Arterial Hypertension [PAH] drugs show promise for children, but efficacy data is limited. Pediatric PAH often differs from adult forms, especially with congenital heart disease, requiring careful consideration of treatment approaches.

Area of Science:

  • Pediatric Cardiology
  • Pulmonary Hypertension Research
  • Pharmacology

Background:

  • Pulmonary Arterial Hypertension (PAH) treatment aims to improve symptoms, survival, and exercise capacity in both children and adults.
  • Pediatric PAH presents distinct characteristics compared to adult PAH, with congenital heart disease being a more frequent underlying cause in children.
  • Established adult PAH treatments may not be directly applicable to pediatric populations due to these etiological differences.

Purpose of the Study:

  • To review novel anti-PAH medications and evaluate existing data on their application in pediatric PAH.
  • To highlight the unique aspects of PAH in children versus adults.
  • To assess the suitability of extrapolating adult PAH drug efficacy to pediatric patients.

Main Methods:

  • Comprehensive literature review of new anti-PAH drugs.
  • Analysis of available clinical data on pediatric PAH treatment.
  • Comparison of PAH etiologies in pediatric and adult populations.

Main Results:

  • Emerging anti-PAH therapies are being investigated for pediatric use.
  • Significant differences in PAH causes exist between children (e.g., congenital heart disease) and adults (e.g., idiopathic PAH).
  • Direct extrapolation of adult PAH drug efficacy to children is not supported by current evidence.

Conclusions:

  • Careful evaluation of new anti-PAH drugs is necessary for pediatric patients.
  • Treatment strategies for pediatric PAH must account for its unique underlying conditions.
  • Further research is crucial to establish effective and safe PAH therapies for children.

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...